Novartis, Pear Therapeutics launch first prescription digital therapeutic for substance use disorder

Novartis' Sandoz unit and Pear Therapeutics announced the commercial launch of the prescription digital therapeutic reSET for patients with substance use disorder (SUD) following approval by the FDA last year. Richard Francis, CEO of Sandoz, said "adding reSET to outpatient therapy enhances behaviours associated with recovery," adding "it leverages new technology to help patients improve abstinence in substances of abuse and stay in treatment programmes longer than outpatient therapy alone."

According to the companies, reSET is a 12-week prescription digital therapeutic to be used in conjunction with outpatient clinician-delivered care. The product offers interactive treatment modules that deliver cognitive behavioural therapy and fluency training to reinforce proficiency. Study results showed that reSET, when used with outpatient therapy and contingency management, significantly improved abstinence in substances of abuse and increased retention as compared to outpatient therapy alone.

In April, Sandoz entered a collaboration with Pear Therapeutics to develop and market prescription digital therapeutics for patients with SUD and opioid use disorders. The deal is part of the Swiss drugmaker's push into emerging digital technologies, which include efforts to monitor patient data in real-time, detect day-to-day behavioural and biological changes in condition and improve patient adherence.

Earlier this year, Novartis launched an app designed to accelerate the development of treatments for ophthalmic diseases by allowing patients in clinical studies to self-report data. The drugmaker previously partnered with Science 37 to start up to 10 new clinical trials over the next three years that will combine virtual and traditional models, enabling patients to participate in studies using mobile devices and telemedicine services.

To read more Top Story articles, click here.